Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway
- 18 January 2000
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 42 (3) , 239-242
- https://doi.org/10.1002/(sici)1097-0045(20000215)42:3<239::aid-pros10>3.0.co;2-g
Abstract
BACKGROUND Interleukin‐6 (IL‐6) is a pleiotropic cytokine that regulates growth and differentiation of various types of malignant tumors, including prostate carcinomas. The levels of IL‐6 are elevated in sera of patients with metastatic prostate cancer. In this study, we evaluate the role of IL‐6 in the growth regulation of prostate cancer cells. METHODS Expression of IL‐6 and its receptors in human prostate cancer cells was measured by ELISA and RT‐PCR. The effects of IL‐6 on cell growth were evaluated by ectopically expressing IL‐6 cDNA into IL‐6‐negative LNCaP human prostate cancer cells. Stat3 DNA binding activities were analyzed by electromobility shift assay and supershift assay. RESULTS Expression of IL‐6 was detected in the androgen‐insensitive prostate cancer cell lines (i.e., TSU, PC3, and DU145), but not in the androgen‐sensitive LNCaP cell line. IL‐6 receptors, including both IL‐6‐specific receptor α chain and gp130 signal transducer, are expressed in all human prostate cancer cell lines (i.e., LNCaP, TSU, PC3, and DU145). Overexpression of IL‐6 by ectopically expressing IL‐6 into IL‐6‐negative LNCaP human prostate cancer cells significantly increased clonogenic ability and cell proliferation in vitro compared to the IL‐6‐negative parental LNCaP cells and the antisense controls. This growth stimulation by IL‐6 was accompanied by activation of the Stat3 signaling transduction pathway. CONCLUSIONS IL‐6 is an autocrine growth factor for LNCaP human prostate cancer cells; the effects of IL‐6 on prostate cancer cell growth are mediated through the Janus kinase‐signal transducers and activators of transcription (JAK‐STAT) signaling pathway. Prostate 42:239–242, 2000.Keywords
This publication has 14 references indexed in Scilit:
- Characterization of the role of IL-6 in the progression of prostate cancerThe Prostate, 1999
- Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2The Prostate, 1999
- ELEVATED LEVELS OF CIRCULATING INTERLEUKIN-6 AND TRANSFORMING GROWTH FACTOR-beta 1 IN PATIENTS WITH METASTATIC PROSTATIC CARCINOMAJournal of Urology, 1999
- Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathwayBiochemical Journal, 1998
- Expression of homeobox gene-GBX2 in human prostatic cancer cellsThe Prostate, 1996
- Retinoic acid normalizes the increased gene transcription rate of TGF–α and EGFR in head and neck cancer cell linesNature Medicine, 1996
- TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT PathwayAnnual Review of Biochemistry, 1995
- Interleukin-6: A candidate mediator of human prostate cancer morbidityUrology, 1995
- Interleukin 6 Receptor mRNA in Prostate Carcinomas and Benign Prostate HyperplasiaJournal of Urology, 1994
- Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomasFEBS Letters, 1989